BACKGROUND: In developed countries, 40% of breast cancer patients are >65 years of age at diagnosis, of whom 16% additionally suffer from diabetes. The aim of this study was to assess the impact of diabetes on relapse-free period (RFP) and overall mortality in elderly breast cancer patients. PATIENTS AND METHODS: Patients were selected from the retrospective FOCUS cohort, which contains detailed information of elderly breast cancer patients. RFP was calculated using Fine and Gray competing risk regression models for patients with diabetes versus patients without diabetes. Overall survival was calculated by Cox regression models, in which patients were divided into four groups: no comorbidity, diabetes only, diabetes and other comorbidity or other comorbidity without diabetes. RESULTS: Overall, 3124 patients with non-metastasized breast cancer were included. RFP was better for patients with diabetes compared with patients without diabetes (multivariable HR 0.77, 95% CI 0.59-1.01), irrespective of other comorbidity and most evident in patients aged ≥75 years (HR 0.67, 95% CI 0.45-0.98). The overall survival was similar for patients with diabetes only compared with patients without comorbidity (HR 0.86, 95% CI 0.45-0.98), while patients with diabetes and additional comorbidity had the worst overall survival (HR 1.70, 95% CI 1.44-2.01). CONCLUSION: When taking competing mortality into account, RFP was better in elderly breast cancer patients with diabetes compared with patients without diabetes. Moreover, patients with diabetes without other comorbidity had a similar overall survival as patients without any comorbidity. Possibly, unfavourable effects of (complications of) diabetes on overall survival are counterbalanced by beneficial effects of metformin on the occurrence of breast cancer recurrences.
BACKGROUND: In developed countries, 40% of breast cancerpatients are >65 years of age at diagnosis, of whom 16% additionally suffer from diabetes. The aim of this study was to assess the impact of diabetes on relapse-free period (RFP) and overall mortality in elderly breast cancerpatients. PATIENTS AND METHODS: Patients were selected from the retrospective FOCUS cohort, which contains detailed information of elderly breast cancerpatients. RFP was calculated using Fine and Gray competing risk regression models for patients with diabetes versus patients without diabetes. Overall survival was calculated by Cox regression models, in which patients were divided into four groups: no comorbidity, diabetes only, diabetes and other comorbidity or other comorbidity without diabetes. RESULTS: Overall, 3124 patients with non-metastasized breast cancer were included. RFP was better for patients with diabetes compared with patients without diabetes (multivariable HR 0.77, 95% CI 0.59-1.01), irrespective of other comorbidity and most evident in patients aged ≥75 years (HR 0.67, 95% CI 0.45-0.98). The overall survival was similar for patients with diabetes only compared with patients without comorbidity (HR 0.86, 95% CI 0.45-0.98), while patients with diabetes and additional comorbidity had the worst overall survival (HR 1.70, 95% CI 1.44-2.01). CONCLUSION: When taking competing mortality into account, RFP was better in elderly breast cancerpatients with diabetes compared with patients without diabetes. Moreover, patients with diabetes without other comorbidity had a similar overall survival as patients without any comorbidity. Possibly, unfavourable effects of (complications of) diabetes on overall survival are counterbalanced by beneficial effects of metformin on the occurrence of breast cancer recurrences.
Entities:
Keywords:
breast cancer; diabetes; elderly; geriatric oncology; metformin; observational study
Authors: Ben Boursi; Bruce J Giantonio; James D Lewis; Kevin Haynes; Ronac Mamtani; Yu-Xiao Yang Journal: Eur J Cancer Date: 2016-03-25 Impact factor: 9.162
Authors: Anna H Wu; Allison W Kurian; Marilyn L Kwan; Esther M John; Yani Lu; Theresa H M Keegan; Scarlett Lin Gomez; Iona Cheng; Salma Shariff-Marco; Bette J Caan; Valerie S Lee; Jane Sullivan-Halley; Chiu-Chen Tseng; Leslie Bernstein; Richard Sposto; Cheryl Vigen Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-25 Impact factor: 4.254
Authors: Charla C Engels; Nienke A de Glas; Anita Sajet; Esther Bastiaannet; Vincent T H B M Smit; Peter J K Kuppen; Caroline Seynaeve; Cornelis J H van de Velde; Gerrit Jan Liefers Journal: Mol Oncol Date: 2015-10-31 Impact factor: 6.603
Authors: Gregory S Calip; Kathleen E Malone; Julie R Gralow; Andy Stergachis; Rebecca A Hubbard; Denise M Boudreau Journal: Breast Cancer Res Treat Date: 2014-10-10 Impact factor: 4.872
Authors: Heidi D Klepin; Brandelyn N Pitcher; Karla V Ballman; Alice B Kornblith; Arti Hurria; Eric P Winer; Clifford Hudis; Harvey J Cohen; Hyman B Muss; Gretchen G Kimmick Journal: J Oncol Pract Date: 2014-07-29 Impact factor: 3.840
Authors: Cristian Tebé; Daniel Martinez-Laguna; Victor Moreno; Cyrus Cooper; Adolfo Diez-Perez; Gary S Collins; Daniel Prieto-Alhambra Journal: J Bone Miner Res Date: 2018-05-03 Impact factor: 6.741